Despite the slightly warmer weather and longer periods of sunshine, we are still in the depths of cold and flu season, a ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

Research reveals that even low levels of air pollution significantly increase the risk of respiratory infections in adults, ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

As health officials report a surge of winter viruses, health experts are warning that heart disease symptoms can sometimes ...

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

Streptococcus pneumonia remains the most common bacterial cause, while viral infections such as influenza, COVID-19, and respiratory syncytial virus (RSV) are particularly common during the winter ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...